The UK’s mergers and acquisitions regulator the Takeover Panel has reportedly posted an annual loss of about $2.7 million due to a fall in deal making and costs related to an international panel recently held.
According to reports, UK’s global M&A performance has fallen short of expectations despite the recent high-profile acquisition approach of AstraZeneca by Pfizer.
Further, an event held last May for global merger regulators also bit into costs as the Panel spent about $2.5 million more on the conference than in previous years.
The UK’s Takeover Panel makes money through merger document fees and taxes for high-cost share acquisitions.
Full content: The Telegraph
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Former DOJ Antitrust Chief Megan Lewis Joins McGuireWoods as Partner
Oct 3, 2024 by
nhoch@pymnts.com
Tech Rivals Push for EU Crackdown on Microsoft Edge Dominance
Oct 3, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh